Navigation Links
Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics
Date:12/21/2007

CHARLOTTESVILLE, Va., Dec. 21 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical stage drug-development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced that one of its key advisors, Mr. Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp(R) (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No. 7,217,689).

Mr. Byrne, who is an Officer of Diffusion Pharmaceuticals and a member of its Board of Directors, has directed the worldwide intellectual property strategy of the Company since its inception in February 2001. His experience includes in-house counsel positions within both Genentech and Amgen.

"We are exceptionally fortunate to have such an experienced pharmaceutical development executive with scientific acumen and expertise in related intellectual property law leading our worldwide patent strategy and helping to guide the company," says David G. Kalergis, Diffusion Pharmaceuticals' Chief Executive Officer.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include critical care uses such as trauma, hemorrhage, stroke and heart attack, and cancer as well as chronic conditions such as cardiovascular disease, respiratory disorders, anemia and peripheral vascular disease. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. The Company's first Phase I clinical trial for its lead molecule, trans sodium crocetinate (TSC), shows the drug is well-tolerated in healthy human subjects at doses significantly higher than the estimated efficacious human dose. Clinical trials will begin in 2008 in peripheral vascular disease patients suffering from intermittent claudication and in cancer patients undergoing radiation therapy. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit http://www.diffusionpharma.com.


'/>"/>
SOURCE Diffusion Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program ... of his grandfather, “Hire for attitude. Train for skill.” , In keeping with this ... Jevohn Miller as a salesman. Zamzow is hoping to replicate the practice throughout the ...
(Date:2/25/2017)... , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change by ... and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Chef Jodi ... wine scene. Making stops in several cities, she gained a number of delicious ... began in Stellenbosch, a town in South Africa’s Western Cape province. It is ...
(Date:2/24/2017)... 2017 Symic Bio, a biopharmaceutical company focused ... of therapeutics, announced today the completion of enrollment for ... disease. The trial will evaluate the safety and efficacy ... reduction of restenosis following angioplasty. "We,re ... SB-030," said Nathan Bachtell , M.D., Chief Medical ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
Breaking Biology News(10 mins):